Key facts
- DaltonTX’s last known valuation is $18.8M (Sep 2025).
- It has raised $5.5M; the latest was Seed Round ($5.5M) in Sep 2025.
- Notable investors include Seedcamp, IQ Capital Partners, Redalpine, Oxford University Innovation.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for DaltonTX
- ·The full record, as it builds
Funding rounds
No funding rounds for DaltonTX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DaltonTX
Operator of a biotechnology firm intended to make drug design more efficient. The company focuses on building an AI ecosystem for drug discovery, solving real-world problems, and enabling the pharmaceutical industry to revolutionize drug discovery, ultimately improving the lives of patients worldwide.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 21
- Website
- daltontx.com/
- Ownership
- Privately Held (backing)
DaltonTX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DaltonTX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DaltonTX in its N-PORT filings yet. We sweep new filings monthly.